MCL1 and acute myeloid leukemia: Additionally, the RAS/MAPK pathway has been observed to mediate resistance to venetoclax through MCL-1 upregulation, which increases metabolic pathways such as fatty acid and amino acid metabolism that drive OXPHOS, conferring resistance to venetoclax in AML [16].